Amylin (20-29) (human)

OC[C@H](N)C(N[C@@H](CC(N)=O)C(N[C@@H](CC(N)=O)C(N[C@H](C(NCC(N[C@@H](C)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CC(C)C)C(N[C@@H](CO)C(N[C@@H](CO)C(O)=O)=O)=O)=O)=O)=O)=O)CC1=CC=CC=C1)=O)=O)=O

[1]Kapurniotu A, et al. Structure-based design and study of non-amyloidogenic, double N-methylated IAPP amyloid core sequences as inhibitors of IAPP amyloid formation and cytotoxicity. J Mol Biol. 2002 Jan 18;315 (3) :339-50.|[2]Elgersma RC, et al. Transformation of the amyloidogenic peptide amylin (20-29) into its corresponding peptoid and retropeptoid: access to both an amyloid inhibitor and template for self-assembled supramolecular tapes. Bioorg Med Chem Lett. 2007 Apr 1;17 (7) :1837-42.